Menhycia® is a China first-in-class and first NDA approved MCV4 vaccine. Compared with existing products in this regard, Menhycia® has significantly improved and upgraded the process of current products by leveraging the Company's advanced synthetic vaccine technology, along with the enhanced formulation and delivery technology. The commercialization of Menhycia® will not only bridge the gap between China and developed countries but also fulfil the demands for high-end vaccines in this field within China by filling the vacancy.

Menhycia® was granted NDA approval by the NMPA in December 2021, making it the first MCV4 vaccine approved in China. Save for Menhycia®, the current quadra-valent meningococcal vaccines in China are all MPSV4 products with a limited age indication. In contrast, our Menhycia® is applicable for children aged from 3 months to 6 years old (83 months), with good safety and immunogenicity profiles demonstrated in clinical trials. The Company has established the Commercial Operation Center (COC) with a comprehensive system to enable the Company's commercialization team to develop and implement domestic and overseas promotion strategies and marketing operations for Menhycia®.

The Company obtained NDA approval from the NMPA in June 2021 for commercialization of Menphecia® in the PRC. Menhycia® have been successfully marketed in 30 provinces and cities in China, and their penetration rate continues to increase.